Skip to main content
Premium Trial:

Request an Annual Quote

Pharmacopeia Completes Spin-Off of PDD; to be Renamed Accelrys Soon

NEW YORK, May 3 (GenomeWeb News) - Pharmacopeia has completed the spin-off of Pharmacopeia Drug Discovery, the company said today.


As of today, Pharmacopeia and PDD will trade as separate companies on Nasdaq under the ticker symbols "ACCL" and "PCOP", respectively. Pharmacopeia plans to change its name to Accelrys upon approval by its stockholders later this month.


Pharmacopeia will be headquartered in San Diego, while PDD will stay in Princeton.

The Scan

Genetic Risk Factors for Hypertension Can Help Identify Those at Risk for Cardiovascular Disease

Genetically predicted high blood pressure risk is also associated with increased cardiovascular disease risk, a new JAMA Cardiology study says.

Circulating Tumor DNA Linked to Post-Treatment Relapse in Breast Cancer

Post-treatment detection of circulating tumor DNA may identify breast cancer patients who are more likely to relapse, a new JCO Precision Oncology study finds.

Genetics Influence Level of Depression Tied to Trauma Exposure, Study Finds

Researchers examine the interplay of trauma, genetics, and major depressive disorder in JAMA Psychiatry.

UCLA Team Reports Cost-Effective Liquid Biopsy Approach for Cancer Detection

The researchers report in Nature Communications that their liquid biopsy approach has high specificity in detecting all- and early-stage cancers.